The NAGA Group AG

  • WKN: A161NR
  • ISIN: DE000A161NR7
  • Land: Deutschland

Nachricht vom 24.11.2021 | 08:55

The NAGA Group AG plans NASDAQ IPO, publishes sales guidance for 2022 and announces changes to its regulated activities in the United Kingdom

The NAGA Group AG / Key word(s): IPO/Forecast
The NAGA Group AG plans NASDAQ IPO, publishes sales guidance for 2022 and announces changes to its regulated activities in the United Kingdom

24-Nov-2021 / 08:55 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement according to Art. 17 Market Abuse Regulations

-The Naga Group AG plans NASDAQ IPO, publishes sales guidance for 2022 and announces changes to its regulated activities in the United Kingdom -

Hamburg, 24th November 2021 - NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for trading, cryptocurrencies and payments NAGA.com, is planning an initial public offering ("IPO") and an associated listing on the US technology exchange NASDAQ for 2022.

NAGA's IPO and listing in the US could be completed as early as the second half of 2022, subject to market conditions and other conditions. Details will be determined by NAGA at a later stage in the process. NAGA expects through the US IPO access to a much broader group of investors and to further significantly strengthen its profile on the capital market.

These efforts are supported by a continuously strong development of the operative business. For the financial year 2022, the company expects consolidated sales of EUR 95 million to EUR 105 million, which corresponds to a approx. doubling of the sales planned for 2021, as well as consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 25 million. up to EUR 30 million.

At the same time, the company announces that its direct business relationships in regards to regulated activities with UK-based customers of the companies within the group are to be terminated in the course of December. The UK's Financial Conduct Authority are aware of this change.

The resulting changes in sales and margins have already been taken into account in the above guidance.

Important Notice:
The Company's shares have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This release is not for distribution, directly or indirectly, in or into the United States, including its territories and possessions. This release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities.


Contact:
The NAGA Group AG
Andreas Luecke
Management Board
Hohe Bleichen 12
20354 Hamburg
T: +49 (0)40 524 77910
E: ir@naga.com


24-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021